Objective:To explore the clinical efficacy of recombinant human interferon α-1b combined with budesonide and sin-gle budesonide aerosol inhalation in the treatment of acute bronchitis in children.Methods:106 children with acute bronchitis were se-lected as study samples,and were divided into control group and study group by adopting different treatment methods,with 53 cases in each group.The children in the control group were treated with budesonide aerosol inhalation inhalation in addition to conventional treatment,while the children in the study group were combined with budesonide and recombinant human interferon α-1b aerosol inhala-tion inhalation on the basis of conventional treatment,both groups were treated for 1 week.The regression times of clinical symptoms,changes in serum inflammatory factors levels[procalcitonin(PCT),serum C-reactive protein(CRP)],blood routine[white blood cell count(WBC),neutrophil percentage(NEU%)]and lung function indexes[maximum expiratory volume in one second(FEV1),FEV1 to forced vital capacity ratio(FEV1/FVC),and maximum expiratory flow(PEF)]before treatment and after 1 week of treatment and adverse reactions during treatment were compared.Results:The regression times of clinical symptoms in study group were shorter than those in control group(P＜0.05).After 1 week of treatment,the levels of serum PCT,CRP,WBC and NEU%were lower in study group than those in control group(P＜0.05).The FEV1/FVC,PEF and FEV1 in study group were higher compared with those in con-trol group(P＜0.05).During treatment,there were no statistical differences in the incidence rates of adverse reactions between both groups(P>0.05).Conclusion:Recombinant human interferon α-1b combined with budesonide aerosol inhalation inhalation for chil-dren with acute bronchitis can quickly relieve the clinical symptoms,and improve the inflammation level,and it has high safety.